In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-10, Vol.15 (10), p.e0240149-e0240149
Hauptverfasser:	Artigas, Laura, Coma, Mireia, Matos-Filipe, Pedro, Aguirre-Plans, Joaquim, Farrés, Judith, Valls, Raquel, Fernandez-Fuentes, Narcis, de la Haba-Rodriguez, Juan, Olvera, Alex, Barbera, Jose, Morales, Rafael, Oliva, Baldo, Mas, Jose Manuel, Srinivasan, Narayanaswamy
Format:	Artikel
Sprache:	eng
Schlagworte:	Artificial intelligence Bioinformatics Biology Biology and Life Sciences Clinical trials Complications Complications and side effects Computer and Information Sciences Coronaviruses COVID-19 Cytokine storm Cytokines Development and progression Drug therapy Drugs Funding Gene expression Infections Injury prevention Medical treatment Medicine and health sciences Melatonin Methods Patient outcomes Patients Pirfenidone Proteins Renal failure Respiratory diseases Respiratory distress syndrome Sepsis Septic shock Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Software Supervision Therapeutic targets Viral diseases Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!